Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Cash from Financing Activities (2016 - 2025)

Lisata Therapeutics' Cash from Financing Activities history spans 13 years, with the latest figure at $205000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 313.54% year-over-year to $205000.0; the TTM value through Dec 2025 reached $599000.0, up 390.78%, while the annual FY2025 figure was $599000.0, 390.78% up from the prior year.
  • Cash from Financing Activities reached $205000.0 in Q4 2025 per LSTA's latest filing, down from $353000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $452000.0 in Q2 2023 to a low of -$142000.0 in Q1 2024.
  • Average Cash from Financing Activities over 3 years is $70727.3, with a median of $24000.0 recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: tumbled 500.0% in 2024, then soared 313.54% in 2025.
  • A 3-year view of Cash from Financing Activities shows it stood at $24000.0 in 2023, then crashed by 500.0% to -$96000.0 in 2024, then surged by 313.54% to $205000.0 in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Cash from Financing Activities are $205000.0 (Q4 2025), $353000.0 (Q3 2025), and $64000.0 (Q2 2025).